COMBINATION THERAPY PRODUCT AND USES THEREOF

摘要

The present invention provides a combination product comprising a first agent that inhibits the biological activity of hCAP18/LL-37; and a second agent that inhibits the biological activity of an EGF receptor, wherein each of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier. In a preferred embodiment, the agent(s) alter the transcription, translation and/or binding properties of hCAP18/LL-37 and/or an EGF receptor. Preferably, the agent(s) are selected from the group consisting of short interfering RNA (siRNA) molecules, antisense oligonucleotides and compounds with binding affinity for hCAP18/LL-37 and/or EGF receptors. The invention further provides methods for inhibiting the proliferation and/or metastasis of cancer cells in a patient, and pharmaceutical compositions for use in the treatment of cancer.